Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

Abstract

Reovirus infection of tumor cells reduces metastatic disease burden and primes antitumor immunity. Future clinical trials should be designed to explore both direct cytotoxic and immunotherapeutic effects of reovirus.